Skip to main content
. 2014 Feb 12;14:25. doi: 10.1186/1471-230X-14-25

Table 4.

Treatment-emergent adverse events reported in ≥5 % of subjects in the teduglutide group

Variable, n (%) Placebo (n = 13) Teduglutide 4 mg (n = 23)
Treatment-emergent AEs
9 (69)
14 (61)
Abdominal distention
2 (15)
8 (35)
Constipation
2 (15)
5 (22)
Headache
2 (15)
5 (22)
Abdominal pain
1 (8)
5 (22)
Nausea
0
5 (22)
Dyspepsia
0
2 (9)
Eructation
0
2 (9)
Extremity pain 0 2 (9)

AE = adverse event.